Issued Patents 2017
Showing 1–20 of 20 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 9834769 | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 | Joseph Collard, Carlos Coito | 2017-12-05 |
| 9834767 | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 | Joseph Collard | 2017-12-05 |
| 9809816 | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG | Joseph Collard | 2017-11-07 |
| 9771593 | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 | Joseph Collard | 2017-09-26 |
| 9771579 | Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA | Joseph Collard, Belinda De Leon, Carlos Coito, Jane Hsiao | 2017-09-26 |
| 9765336 | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO | Joseph Collard | 2017-09-19 |
| 9745582 | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 | Joseph Collard | 2017-08-29 |
| 9745584 | Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4 | Joseph Collard | 2017-08-29 |
| 9745580 | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 | Joseph Collard | 2017-08-29 |
| 9732339 | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 | Joseph Collard | 2017-08-15 |
| 9725756 | Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP | Joseph Collard, Carlos Coito | 2017-08-08 |
| 9725717 | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3 | Joseph Collard | 2017-08-08 |
| 9714423 | Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 | Joseph Collard | 2017-07-25 |
| 9708604 | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 | Joseph Collard, Carlos Coito | 2017-07-18 |
| 9677074 | Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3) | Joseph Collard | 2017-06-13 |
| 9663785 | Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1 | Joseph Collard | 2017-05-30 |
| 9624493 | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 | Joseph Collard | 2017-04-18 |
| 9611477 | Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP | Joseph Collard | 2017-04-04 |
| 9593330 | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN | Joseph Collard | 2017-03-14 |
| 9533004 | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family | Joseph Collard | 2017-01-03 |